Self-regulatory codes of conduct: Are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners?

International Journal of Health Services

Volumn 28, Issue 2, 1998, Pages 269-279

  Roughead, Elizabeth E ^a   Gilbert, Andrew L ^b   Harvey, Ken J ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; ETHICS; GENERAL PRACTITIONER; MEDICAL PRACTICE;

EID: 0031898157     PISSN: 00207314     EISSN: None     Source Type: Journal    
DOI: 10.2190/B81X-4A53-TY5M-C2HR     Document Type: Article

References (22)

1. Greenwood, J. Markrting Medicine-What Really Works and Why. REMIT Consultants, London, 1991.
2. Peay, M. Y., and Peay, E. R. The role of commercial sources in the adoption of a new drug. Soc. Sci. Med. 26(12): 1183-1189, 1988.
3. Pharma promotion debated. Scrip 1579/80: 9, 1990/91.
4. Gambrill, J., and Bridges-Webb, C. Use of sources of therapeutic and prescribing information by general practitioners. Aust. Fam. Physician 9: 482-484, 1980.
5. Australian Pharmaceutical Manufacturers Association. Code of Conduct of the Australian Pharmaceutical Manufacturers Association Inc. 10. Nth, Sydney, 1993.
6. Langman, M. The code for promoting drugs can do little to limit overenthusiastic advocacy. BMJ 297: 499-500, 1988.
7. Herxheimer, A., and Collier, J. Promotion by the British pharmaceutical industry, 1983-88: A critical analysis of self regulation. BMJ 300: 307-311, 1990.
8. Moulds, R. F. W., Bochner, R, and Wing, L. M. H. Drug advertising (letter). Med. J. Aust. 145: 178-179, 1986.
9. Moulds, R. F. W., and Wing, L. M. H. Drug advertising (letter). Med. J. Aust. 150: 410-411, 1989.
10. Moulds, R. F. W., et al. Drug advertising (letter). Med. J. Aust. 147: 52, 1987.
11. Carandang, E. D., and Moulds, R. F. W. Pharmaceutical advertisements in Australian medical publications - Have they improved? Med. J. Aust. 161: 671-672, 1994.
12. Trade Practices Commission. Final Report by the Trade Practices Commission of the Self-regulation of Promotion and Advertising of Therapeutic Goods. Aussie Print, Canberra, 1992.
13. Miller, M. APMA code of conduct report, 1 January 1993-30 June 1993. Med. J. Aust. 159: 539, 1993.
14. Hemminki, E. Content analysis of drug-detailing by pharmaceutical representatives. Med. Educ. 11(3): 210-215, 1977.
15. Hemminki, E. Commercial information on drugs: Confusing the physician? J. Drug. Issues 18(2): 2457, 1988.
16. Bardelay, D. French doctors report on sales representatives' visits. Essential Drugs Monitor 17: 21, 1994.
17. NUDIST: Non-numerical Unstructured Data Index Searching and Theory-building. The software for qualitative data analysis. NUDIST Project, QRS, La Trobe University, Bundoora, Australia.
18. World Health Organization. Ethical Criteria for Medicinal Drug Promotion, 1988. Geneva, 1988.
19. Association of the British Pharmaceutical Industry. Code of Practice for the Pharmaceutical Industry 1996. Prescription Medicines Code of Practice Authority, London, 1996.
20. Researched Medicines Industry. Code of Practice Representing the Research-Based Pharmaceutical Industry, Wellington, New Zealand, 1994.
21. Ziegler, M. G., Lew, P., and Singer, B. C. The accuracy of drug information from pharmaceutical sales representatives. JAMA 273(16): 1296-1298, 1995.
22. Howes, L. G. Critical Assessment of ACE Inhibitors. Victorian Drug Usage Advisory Committee, Melbourne, 1994.